Skip to main content
Top

25-09-2020 | EASD 2020 | Conference coverage | Article

EMPEROR-Reduced: Empagliflozin benefits in HF patients irrespective of diabetes

print
PRINT
insite
SEARCH

Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).

Read the transcript

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »